申请人:Adir et Compagnie
公开号:US06350759B1
公开(公告)日:2002-02-26
Compound of formula (I):
wherein:
R1 represents hydrogen or
wherein A is as defined in the description,
R2 and R3 each independently represents alkyl, cycloalkyl, heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, cycloalkylalkyl, heterocycloalkylalkyl, optionally substituted arylalkyl, optionally substituted heteroarylalkyl,or optionally substituted aminoalkyl or R2 and R3, together with the carbon atom carrying them, form cycloalkyl or monocyclic heterocyclic group, substituted or unsubstituted,
R40 represents hydrogen or a group selected from optionally substituted alkyl, optionally substituted alkenyl and optionally substituted alkynyl or Q or —V—Q wherein V represents alkylene, alkenylene or alkynylene and Q represents optionally substituted cycloalkyl, optionally substituted aryl, optionally substituted heterocycloalkyl,or optionally substituted heteroaryl,
R41 and R5 together form a bond or each represents hydrogen,
R6, R7, R8 and R9 each independently represents hydrogen, halogen, alkyl, (C3-C8)cycloalkyl,or —OW wherein W is as defined in the description, and medicinal products containing the same which are useful as antioxidative agents.
化合物的结构式(I)如下所示:其中:R1代表氢,或者A如描述中定义,R2和R3各自独立代表烷基、环烷基、杂环烷基、可选择取代芳基、可选择取代杂芳基、环烷基烷基、杂环烷基烷基、可选择取代芳基烷基、可选择取代杂芳基烷基,或者可选择取代
氨基烷基,或者R2和R3与携带它们的碳原子一起形成环烷基或单环杂环基,取代或未取代;R40代表氢或从可选择取代烷基、可选择取代烯基和可选择取代炔基或Q或—V—Q中选择的基团,其中V代表烷基、烯基或炔基,Q代表可选择取代环烷基、可选择取代芳基、可选择取代杂环烷基,或者可选择取代杂芳基;R41和R5一起形成键或各自代表氢;R6、R7、R8和R9各自独立代表氢、卤素、烷基、(C3-C8)环烷基,或者—OW,其中W如描述中定义;含有这些化合物的药品可用作
抗氧化剂。